Related Experiment Video

Updated: Jul 11, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Additional treatment for pT3 prostate cancer: now, later or never

David P Dearnaley1

  • 1Academic Radiotherapy, Institute of Cancer Research, Sutton, Surrey, UK.

BJU International
|September 14, 2007
PubMed
Summary

No abstract available in PubMed .

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Related Experiment Videos

Last Updated: Jul 11, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.

The Lancet. Oncology·2025

Radiation-induced lymphocyte apoptosis and chromosomic aberrations for prediction of toxicities in patients undergoing radical radiotherapy for breast or prostate cancers.

The British journal of radiology·2025

Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024

Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types.

JNCI cancer spectrum·2023

Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Antegrade versus retrograde ureteroscopy for large proximal ureteric stones: a meta-analysis.

BJU international·2026

Evaluation of triplet therapy combined with robot-assisted cytoreductive prostatectomy for high-volume metastatic prostate cancer: a multicentre randomised controlled trial protocol.

BJU international·2026

Immediate intraoperative detrusor muscle status at primary transurethral resection of bladder tumour: a prospective, blinded, paired cohort, feasibility study using fluorescence confocal microscopy (IB1-LaserComplete study).

BJU international·2026

Spontaneous stone passage prediction in acute ureteric colic using radiomics and machine learning.

BJU international·2026

Real-time artificial intelligence-based anatomy recognition in single-port transvesical enucleation of the prostate.

BJU international·2026

Long-term oncological outcomes from a prospective cohort of patients with localised prostate cancer.

BJU international·2026

Case Report: Synchronous germline BAP1-negative choroidal melanoma and clear cell renal cell carcinoma characterized by pan-cancer genomic profiling.

Frontiers in oncology·2026

Paraneoplastic dermatomyositis-like syndrome preceding diagnosis of small cell lung cancer: a case report.

Frontiers in oncology·2026

Conventional osteosarcoma of the ilium masquerading as a brown tumor in primary hyperparathyroidism: a rare case report and literature review.

Frontiers in oncology·2026

Beyond the P Value: A Systematic Framework for Interpreting Oncology Clinical Trials.

JCO precision oncology·2026

Acute adrenal crisis after orchiectomy for testicular adrenal rest tumors in untreated congenital adrenal hyperplasia.

JCEM case reports·2026

The great masquerader: a case report of intrathyroidal hypofunctional normocalcemic parathyroid carcinoma mimicking a benign thyroid nodule.

Gland surgery·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us